Harrison, C. N., Schaap, N., Vannucchi, A. M., Kiladjian, J., Tiu, R. V., Zachee, P., . . . Mesa, R. A. (2017). Janus kinase-2 inhibitor fedratinib in patients with myelofibrosis previously treated with ruxolitinib (JAKARTA-2): A single-arm, open-label, non-randomised, phase 2, multicentre study. Lancet Haematol.
Citação norma ChicagoHarrison, Claire N., et al. "Janus Kinase-2 Inhibitor Fedratinib in Patients With Myelofibrosis Previously Treated With Ruxolitinib (JAKARTA-2): A Single-arm, Open-label, Non-randomised, Phase 2, Multicentre Study." Lancet Haematol 2017.
MLA citiranjeHarrison, Claire N., et al. "Janus Kinase-2 Inhibitor Fedratinib in Patients With Myelofibrosis Previously Treated With Ruxolitinib (JAKARTA-2): A Single-arm, Open-label, Non-randomised, Phase 2, Multicentre Study." Lancet Haematol 2017.